Dr. Jeffrey T. Apter, GCT President, is now at 11th Clinical Trials on Alzheimer’s Disease which takes place on October 24-27 in Barcelona, Spain.
The aim of the conference is to overcome the hurdles and speed the development of effective treatments. These days clinical trial teams from worldwide centers report on their efforts to identify new biomarkers of Alzheimer’s disease as well as more sensitive clinical assessment tools to identify those at risk for AD, to predict progression, and assess the effectiveness of new treatments.